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Many theories have been debated to 
explain the occurrence of SAH-induced 
acute cerebral ischemia. It is widely 
 accepted that most of the complications 
following SAH can be attributed to lumi-
nal narrowing of the major intracranial 
vessels. This mechanism, however, can not 
account for the diffuse brain ischemia, 
brain edema, blood–brain barrier (BBB) 
dysfunction and altered cerebrovascular 
reactivity that are observed frequently 
following SAH (3). Therefore, other mech-
anisms, such as cerebral micro circulatory 
dysfunction, may be implicated as con-
tributory causes in the pathogenic cascade 
after SAH. Acute cerebral ischemia has 
been partially related to a decrease in 
cerebral perfusion pressure (CPP) (4). 
However, experimental and clinical stud-
ies have shown that CPP does not usually 
reach the point of perfusion arrest (5,6), 
suggesting that the decrease in CPP can-
not fully explain the SAH-induced acute 
cerebral ischemia. Furthermore, it has 
the bleeding and a delayed vasospasm 
that occurs more than 48 h later (1,2). 
Although many studies have extensively 
identified the delayed vasospasm as the 
major complication in patients affected 
by aneurysmal SAH, the physiopatho-
logical and clinical importance of acute 
vasoconstriction, a phenomenon well 
documented in experimental settings (1), 
remains to be elucidated in humans. 
In this regard, considerable evidence has 
accumulated suggesting that immediate 
vasoconstriction produces the acute cere-
bral ischemia that typically follows SAH.
INTrODUCTION
Cerebral vasoconstriction following 
aneurysmal subarachnoid hemorrhage 
(SAH) can produce cerebral ischemia, 
neu rological disability and premature 
death. To date, there are no truly effec-
tive treatments for this condition, and 
numerous experimental and clinical 
studies have been performed in the 
poten tial development of effective ther-
apeutic strategies. It is well known that 
cerebral arteries respond to SAH with a 
biphasic contraction: an acute vasocon-
striction that begins minutes following 
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human life (17). Recent studies have 
shown that astrocytes and neurons 
express both EPO and EPOR (16,18,19). 
Microglia, although not a source of EPO, 
produce EPOR mRNA (20) and synthe-
size EPO protein (21).
Further, hypoxia induces EPO express-
ion in cultured astrocytes (16,22) and 
rodent and primate brain (15,16,23). 
The knowledge that cells of the nervous 
system express EPO and its receptor sup-
port a function of EPO as an autocrine–
paracrine factor outside the bone marrow.
A crucial mechanism by which EPO 
exerts neuroprotective actions is via the 
inhibition of apoptosis in the tissue adja-
cent to a lesion (24). Further studies have 
demonstrated that EPO additionally can 
modulate NO synthesis in the vascular 
endothelium (25), promote neurotrans-
mitter release (26,27) and counteract the 
BBB dysfunction that is induced by vas-
cular endothelial growth factor (VEGF) 
(28) or inflammation (29).
The emerging understanding is that 
EPO protects and repairs tissue dam-
age that result from the activation of an 
innate inflammatory response. Primary 
triggers of the various molecular path-
ways of the innate inflammatory response 
are proinflammatory cytokines and the 
hypoxia- inducible factor (HIF). The latter 
is a protein that initiates the synthesis of 
genes encoding for EPO, VEGF, glucose 
transporters and glycolytic enzymes (30).
The tissue-protective molecular path-
ways that are triggered by EPO have 
simi larities to, as well as differences from, 
those activated during erythropoiesis.
It has been proposed that a different 
receptor than EPOR specifically medi-
ates tissue protection (31). In this regard, 
the hematopoietic and tissue-protective 
acti vities could be separated occurring 
the hormonal and neuroprotective 
 actions of EPO via a different signaling 
systems (32). Based on this information, 
engineered molecules have been devel-
oped that  mediate tissue protection but 
do not bind to erythroid progenitors, 
thereby dissociating the biology of EPO- 
mediated cytoprotection from that of 
erythropoiesis (32,33).
prised of an extracellular and intracellular 
domain. A single EPO molecule binds 
to two assembled receptor units on the 
cell surface, and tyrosines located in the 
intracellular domain are consequently 
phosphorylated. This process triggers 
an intracellular signaling cascade that 
regulates gene expression in the nucleus, 
which in turn controls cell survival, pro-
liferation and differentiation (13).
The binding of EPO to EPOR is not the 
only signaling pathway of relevance in 
EPO function, since the common recep-
tor (βCR), a shared receptor subunit of 
interleukin-3 (IL-3), IL-5 and granulocyte 
macrophage colony stimulation factor 
(GM-CSF) receptors, also mediates sev-
eral nonhematopoietic effects of EPO in 
various types of cells by forming a heter-
oreceptor with EPOR subunits (33,53–55).
At the beginning, EPO was well known 
for the function in maintaining tissue 
oxy genation by regulating the number of 
erythrocytes in a negative-feedback control 
system that operates between the kidney 
and the bone marrow. Tissue  hypoxia 
causes a 50-fold or more increase of the 
EPO level in the serum. EPO is  required 
for erythroid development, allow ing matu-
ration of erythroid precursors by inhibiting 
programmed cell death. The  antiapoptotic 
activity is transduced by a signaling 
pathway involving the phos phorylation of 
Janus tyrosine kinase 2 (JAK2). JAK2 in turns 
activates  secondary signaling molecules such 
as signal transducer and activator of tran-
scription (STAT), Ras–mitogen-activated 
protein kinase (MAPK) and phosphatidy-
linositol 3-kinase (PI3K). In erythroid pro-
genitor cells, this mechanism results in the 
upregulation of antiapoptotic proteins of 
the B-cell leukemia/lymphoma 2 (BCL2) 
family, such as BCL-XL (14).
The discovery that EPO has biological 
functions apart from regulating erythro-
poiesis was unexpected and is supported 
by numerous studies. It has been pointed 
out that EPO and EPOR are localized in 
brain areas and spinal cord (15,16). Immu-
nohistochemical studies have demon-
strated that EPO and its receptors have a 
particular distribution in the developing 
human brain since the first stages of 
been suggested that acute ischemia follow-
ing SAH can be asso ciated with a sudden 
and long-lasting decrease in cerebral 
blood flow (7). It has been pointed out 
that alteration in the  nitric oxide (NO) 
vasodilatory system may play a role in 
acute cerebral vaso constriction and isch-
emia following aneu rysmal SAH (8).
Hence, neuroprotection may be an 
 eff ective strategy to counteract the dam-
age affecting neurons and glial cells after 
aneurysmal SAH. Neuroprotective drugs 
potentially could block the cellular, bio-
chemical and metabolic processes that ulti-
mately lead to brain injury. Accordingly, 
an ideal addition to the current SAH 
treatment armamentarium would be a 
well-tolerated neuroprotective agent 
with the ability to reduce arterial vaso-
spasm and the delayed ischemic neuro-
logic deficit. Thus far, a few candidate 
molecules have been investigated and, 
among these, the hormone erythropoie-
tin (EPO) has shown promising results.
ErYTHrOPOIETIN
Erythropoietin is present in all the ver-
tebrates and is a 165-amino acid (~30 kDa) 
glycoprotein and a member of the type I 
cytokine superfamily. It is the primary 
hormone that regulates the differenti-
ation and proliferation of immature eryth-
roid cells (9). This cytokine was cloned 
in 1985 (10) and rapidly adapted into 
clinical practice. Subsequently, its recom-
binant form (rHuEPO) has significantly 
improved the management of anemia 
in chronic renal failure and has greatly 
improved the quality of life for dialysis 
patients. In the fetus, EPO is produced in 
the liver until late gestation and, there-
after, a switch is initiated gradually from 
the liver to the kidney, which is com-
pleted after birth (11). In the adult, the 
kidney is the predominant source of EPO, 
with about 10–15% being generated by 
the liver and possibly other organs (11).
During erythropoiesis, EPO acts by 
binding to its receptor (EPOR) to stimu-
late the proliferation, differentiation and 
maturation of erythroid progenitor cells 
(12). EPOR, a member of the cytokine- 
receptor type I superfamily and is com-
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and ischemic neuronal damage (52). 
The main responsible agent in causing 
endothelial impairment appears to be 
either oxyhemoglobin or bilirubin (49), 
with oxyhemoglobin proposed as able 
to scavenge NO, inactivate guanylate 
cyclase (GC) or increase production of 
oxygen radicals.
It has been reported that βCR may play 
an integrative role in the EPO signaling- 
mediated activation of eNOS in ECs 
through a Src/JAK2/Akt pathway (56). 
Taking the classic EPOR and βCR interac-
tion collectively, substantial evidence has 
shown that EPO has several protective 
effects on the vascular system through the 
NO system, although the detailed molec-
ular mechanisms underlying such inter-
action remain to be determined (42,57,58). 
In this regard, EPO has shown to promote 
EC angiogenesis by an eNOS-dependent 
mechanism (59–61). Furthermore, EPO 
protects cardiac myocytes against isch-
emia-induced injury and apoptosis by 
increasing eNOS activation or protein 
expression (62,63). In an isolated rat heart 
ischemia-reperfusion model, pretreatment 
with EPO provides cardioprotection that 
is dependent on NO (64).
It has been demonstrated that EPO 
promotes proliferation, migration and 
tube formation in ECs (41,42). Blocking 
βCR and EPO-induced activation of Src/
JAK2/Akt signaling pathway inhibited 
the EPO-induced increase in prolifer-
ation, migration and tube formation, 
which indicates the critical role of βCR in 
EPO-mediated beneficial effects on ECs 
(56). In experimental intracerebral hemor-
rhage, EPO reduced inflammation around 
the hematoma and acti vated eNOS, lead-
ing to improved perfusion (65).
NO also has an important role as a 
neuroprotectant in traumatic brain injury 
(TBI). In an experimental model of TBI, 
administration of l-arginine increased 
NO levels in cerebral microdialyzate, 
restored CBF to near preinjury levels 
and reduced the contusion volume (66). 
Pretreatment with EPO administration 
resulted in a significant CBF recovery in 
the penumbra within 2 h after the injury 
by a NO-dependent mechanism (67).
understood (43). Figure 1 illustrates the 
main intracellular EPO signaling path-
ways associated with neuroprotection.
Endothelium-derived NO is one of the 
main regulators of the vessel tone. The 
 activity of endothelial NO synthase (eNOS) 
promotes NO production in endothelial 
cells (ECs) (44). eNOS is regulated by a 
complex signaling network including 
 kinase-dependent signaling pathways 
such as PI3K/Akt, Src and JAK2 in res-
ponse to different stimuli (45-47).
Under normal conditions, NO pro-
vides vasodilation of the microcircula-
tion and maintenance of normal vascular 
tone, antithrombotic effects, prevention 
of excess platelet adhesion and aggrega-
tion, inhibition of endothelial apoptosis, 
as well as vascular smooth muscle cell 
hyperplasia. NO released from ECs dif-
fuses to adjacent smooth muscle cells 
and activates soluble guanylate cyclase 
(GC). GC, in turn, produces cyclic gua-
nosine monophosphate (cGMP), which 
activates intracellular calcium pumps 
sequestering free Ca2+ into sarcoplasmic 
reticulum and relaxing smooth muscle 
cells (48). Dysregulation of eNOS has 
been reported in several vascular dis-
eases, including aneurismal SAH. Fol-
lowing hemorrhage, hemoglobin binds 
NO, thus reducing its availability (49). 
Accordingly, scavenging of NO results 
in a decrease of GC activity, which, in 
return, causes vasoconstriction. Further-
more, hemoglobin has shown to directly 
inactivate GC by oxidization, thus 
leading to reduced production of cGMP 
(50). Furthermore, after SAH, increased 
oxidative stress can uncouple eNOS via 
Zn2+ thiolate oxidation, or, theoretically, 
by tetrahydrobiopterin depletion or oxi-
dation, resulting in a paradoxical release 
of superoxide anion radical, further 
exacerbating oxidative stress and micro-
vascular damage (51, Figure 2).
To date, endothelial mechanisms are 
considered to be the main contributors 
to induced vasospasm (52). It has been 
reported that NO level decreases acutely 
within 10 min after SAH both in exper-
imental models and in humans, leading 
cerebrovascular relaxation impairment 
ErYTHrOPOIETIN sIGNaLING 
PaTHWaYs IN THE NErVOUs sYsTEM
The mechanism by which rHuEPO acts 
in the central nervous system across the 
BBB remains a matter of controversy. EPO 
exerts its neuroprotective effects by act-
ing through several signaling pathways. 
In the bone marrow, the EPO binding to 
its receptor results in phosphorylation 
of JAK2. Upon JAK2 phosphorylation 
and activation, the signaling propagates 
through the MAPK or the protein kinase 
B (PKB/Akt)–nuclear factor-κB (NF-κB) 
pathways (34). In erythroid cells, MAPK 
activation promotes the accumulation of 
the antiapoptotic protein BCL-XL by the 
inhibition of caspases. Also, EPO appears 
to prevent apoptotic injury through an 
Akt-dependent mechanism (35).
Substantial evidence also indicates 
that EPO mediates protective effects by 
maintaining normal vascular autoregu-
lation. This has clinical relevance in pa-
thologies such as stroke, traumatic brain 
injury (TBI), spinal cord injury (SCI) and 
aneurismal SAH. The principal mech-
anism of this protective mechanism 
appears to depend upon NO signaling 
via increased endothelial NO synthase 
(25), which mediates vascular relaxation 
and blood flow preservation. This obser-
vation could explain the remarkable effi-
cacy of EPO in reversing the vascular 
spasm that accompanies subarachnoid 
hemorrhage (36–38) and spinal cord com-
pression (39,40), which, in turn, reduces 
tissue  damage. Moreover, recent studies 
reported that EPO promotes neovascu-
larization through an Akt-dependent 
activation of eNOS in endothelial pro-
genitor cells (EPCs) (41,42). Thus, the 
ability of EPO to counteract cerebral vaso-
spasm may be related to a direct effect 
on the vascular endothelium rather than 
a direct action on cerebral parenchyma. 
The recognized ability of EPO to activate 
protein kinase B (Akt) and subsequent 
phosphorylation of eNOS in endothelial 
cells suggests that increased formation 
of NO could be an important mecha-
nism underlying the therapeutic effect 
of EPO, although the definitive interac-
tion between EPO and NO is not fully 
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injury produced in several experimental 
models of brain insult. In this regard, 
many studies have shown a neuroprotec-
tive effect of EPO in models of cerebral 
ischemia (21,71–75), concussive brain 
injury (76,77), experimental autoimmune 
encephalomyelitis (78) and kainate- 
induced seizures (79). In these experimen-
tal studies, EPO has been administered 
both intrathecally or systemically, pro-
voking controversy regarding the ability 
to cross the BBB. It has been reported 
that systemic administration of rHuEPO, 
following experimental SAH, reduces 
the mortality rate, improves functional 
Further studies are necessary to better 
understand the potential roles exerted by 
EPO and its derivatives in the plasticity 
and tissue protection of the nervous 
system. Although the exact mechanisms 
underlying the interaction between EPO 
and NO system are unclear, overall these 
findings have implications for treat ment 
of brain injury following SAH.
FrOM BENCH TO BEDsIDE
During the past several years, interest 
has focused on the efficacy of recombi-
nant human EPO (rHuEPO) as a neuro-
protective agent against neurological 
Previous investigations have demon-
strated an acute decrease in cerebral NO 
levels after SAH (8) and a significant 
improvement of NO system activity 
after administration of EPO (27,68,69), 
suggesting that EPO could act against 
vasospasm by enhancing the endothelial 
release of NO during the early stage of 
SAH. In experimental SAH, gene trans-
fer of EPO following intracisternal blood 
injection increased the phosphorylation 
of Akt and eNOS, resulting in increased 
NO production in the basilar arteries, 
suggesting the beneficial effect of EPO 
during SAH (70).
Figure 1. Main EPO signaling pathways. Following the EPO binding with the complex EPO receptor (EPOR) and β common receptor 
(βCR), Janus tyrosine kinase 2 (JAK2) is activated. At this time, a secondary signaling pathway involves mitogen-activated protein 
kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) and nuclear factor-κB (NF-κB). Signal transduction and activator of transcription 
5 (STAT5) can also be triggered. These processes allow an increase in antiapoptotic proteins of the B-cell leukemia/lymphoma (BCL) 
 family. Some of the pathways act directly, while others indirectly by inhibiting the activity of a group of enzymes called caspases. These 
are key mediators of apoptosis and are responsible for the degradation of antiapoptotic proteins. EPO also inhibits glycogen synthase 
kinase 3β (GSK3β), which, in turn, prevents the mitochondrial permeability transition pore, a key factor of cell death, through caspase 
activation. Finally, EPO modulates the activity of calcium channels through phospholipase C (PLC), thus reducing the release of excit-
atory neurotransmitters and increasing the production of nitric oxide (NO). Moreover, recent studies reported that EPO promotes neo-
vascularization through an Akt-dependent activation of eNOS in endothelial progenitor cells. The recognized ability of EPO to activate 
protein kinase B (Akt) and subsequent phosphorylation of eNOS in endothelial cells suggests that increased formation of NO could be 
an important mechanism underlying the therapeutic effect of EPO.
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important finding provided by this study 
was the observation that the concentra-
tion of EPO in the cerebrospinal fluid 
(CSF), assessed before euthanization of 
the animals, was significantly higher in 
the rHuEPO-treated animals than in the 
other groups, suggesting for the first time 
that systemically-administered EPO by 
crossing the BBB can result in increased 
EPO concentrations within the CSF. In 
a subsequent study, rabbits were given 
intraperitoneal injections of rHuEPO 
(1,000 IU/kg) starting 5 min after the induc-
tion of SAH and repeated every 8 h for 72 h 
(37). The authors aimed to investigate the 
ability of exogenous administered EPO 
to exert a vascular effect and, in partic-
ular, to counteract the spastic response 
of the cerebral arteries during SAH. By 
test performed at 24, 48 and 72 h after 
SAH showed an increase in locomotor 
activity at 72 h in the placebo-treated 
group, while no increase in locomotor 
activity was observed in rabbits treated 
with rHuEPO.
Subsequently, the efficacy of rHuEPO 
has been evaluated on acute cerebral isch-
emia following experimental SAH in a 
rabbit model (36,80). Histological anal-
ysis performed 24 h following injury 
docu mented a reduction in brain isch-
emic damage in animals given rHuEPO 
(1,000 IU/kg). In particular, analysis of 
cortical neurons showed that the EPO- 
treated rabbits presented with a significant 
decrease in the amount of necrotic neu-
rons compared with the untreated and 
placebo-treated animals (80).  Another 
outcome, and prevents brain ischemic 
damage (37,38,80–88). Given these find-
ings, and according to reports that have 
demonstrated that EPO enhances the NO 
system activity (27,68,69), and neuropro-
tective effects on cerebral cortical neurons 
from N-methyl-d-aspartate receptor- 
mediated glutamate toxicity (71), we fur-
ther investigated the potential protective 
effects of rHuEPO in a rabbit model of 
SAH. Briefly, after experimental SAH has 
been induced by intracisternal blood injec-
tion, the results showed an improvement 
in functional recovery and mortality rate 
following systemic rHuEPO administra-
tion (1,000 IU/kg) for 72 h post-SAH (81). 
Interestingly, all EPO-treated animals 
survived, while 42.9% of placebo-treated 
animals died within 72 h. An open-field 
Figure 2. Main metabolic pathways involving NO in SAH. In endothelial cell (EC), NO is produced by NO synthase (eNOS) action. The 
soluble NO released from endothelial cells diffuses to adjacent smooth muscle cell (SMC) and activates soluble guanylate cyclase 
(GC). GC, in turn, produces cyclic guanosine monophosphate (cGMP), which activates intracellular calcium pumps thus sequestering 
free Ca2+ into intracellular sarcoplasmic reticulum and relaxing SMC. Following aneurysm bleeding hemorrhage, hemoglobin (Hb) binds 
NO thus reducing its availability. Hence, scavenging of NO results in a decrease of GC activity, which in return causes vasoconstriction. 
Furthermore, Hb directly inactivates GC by oxidization, thus leading to reduced production of cGMP. Finally, increased oxidative stress 
uncouples eNOS via Zn2+ thiolate oxidation resulting in a release of superoxide anion radical, further exacerbating oxidative stress and 
microvascular damage. 
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Doppler ultrasonography. Secondary end-
points were incidence of delayed isch-
emic deficits and outcome at discharge 
and at 6 months. As result, although no 
differences were demonstrated in the 
incidence of vasospasm and adverse 
events between the two groups, patients 
receiving EPO had a decreased incidence 
of severe vasospasm, reduced DIDs, a 
shortened duration of impaired autoreg-
ulation and more favorable outcome at 
discharge.
In spite of some limitations, includ-
ing a small number of cases, a single 
EPO dose, a single center and a lack of 
scheduled computed tomographic scan 
examinations, the study demonstrates 
in humans what was already observed 
in experimental studies (88). EPO admi-
nistration can be effective in limiting 
cerebral vasospasm and ischemia after 
aneurysmal SAH.
The interesting features observed in 
experimental and clinical studies suggest 
new therapeutic strategies. Some issues, 
however, should be considered. The 
first concern is the safety of recombinant 
human EPO administration in the setting 
of SAH. It should be considered that 
the current information about the safety 
of this drug in humans comes from its 
use in anemic patients. Translating such 
information from anemic therapy to 
SAH-affected patients can be critical, 
since many pieces of information regard-
ing the interaction and influence between 
EPO and physiologic variables, as well 
as with common therapy administered to 
patients with SAH, are unknown.
Second, several lines of evidence sug-
gest that chronic EPO administration 
can produce hypertension, hypertensive 
encephalopathy, accelerated atheroscle-
rosis, seizures and thrombotic/vascu-
lar events (82). In a model of embolic 
stroke in rats, EPO (5,000 U/kg) in 
combination with tissue plasminogen 
activator (tPA) exacerbated tPA-induced 
brain hemorrhage without reduction of 
ischemic brain damage when adminis-
tered 6 h after stroke by upregulating 
matrix metalloproteinase-9, NF-κB, 
and interleukin-1 receptor-associated 
such as bcl-2 and bcl-xL, were upregu-
lated after injections of rhEPO. Recently, 
the effect of EPO and darbepoetin-α (DA), 
a novel EPO-derived agent with an exten-
ded circulatory half-life and an increased 
in vivo biological activity greater than 
EPO, were assessed in a rabbit model 
of SAH (92). Both erythropoietin and 
darbepoetin α treatments were found to 
 attenuate cerebral vasospasm and pro-
vide neuroprotection after SAH.
Based on the experimental evidence 
suggesting an efficacious EPO-based ther-
apy in SAH (86), clinical trials blossomed, 
however, with uncertain results (93,94). In 
this regard, the first clinical trial was ter-
minated preliminarily, with inconclusive 
results, because of a lower than expected 
inclusion rate (93). Seventy- three patients 
were randomized to treat ment with EPO 
(500 IU/kg/day for three days) or placebo. 
The primary end point was Glasgow 
Out come Score at six months. Surrogate 
measures of secondary ischemia, that is, 
transcranial Doppler (TCD) flow velocity, 
sym pto matic vasospasm, cerebral meta-
bolism and jugular venous oximetry, 
bio chemical markers of brain damage 
and blood–brain barrier integrity were 
assessed. The study failed in assessing 
the primary endpoint due to the limited 
sample size. Furthermore, except for an 
increased EPO concentration in the CSF 
of the EPO-treated group, there were no 
statistically significant group differences 
in the primary or secondary outcome 
measures.
A recent Phase II, proof-of-concept 
trial tested the hypothesis that acute sys-
temic EPO therapy in patients following 
aneurismal SAH can reduce cerebral 
vaso spasm and shorten impaired auto-
regulation as primary endpoints, which 
subsequently decrease delayed ischemic 
deficits (DIDs) and improve clinical 
out come as secondary endpoints (94). 
Within 72 h following aneurysm bleed-
ing, 80 patients were randomized to 
receive intravenous EPO (30,000 U) or 
placebo every 48 h for a total of 90,000 U. 
Primary endpoints were the incidence, 
duration and severity of vasospasm and 
impaired autoregulation on transcranial 
morphometric analysis of the basilar 
artery, the authors observed that the 
administration of rHuEPO significantly 
reduced the vasoconstriction in SAH-
plus-rHuEPO-treated animals compared 
with other animals that underwent 
SAH. Patho logical findings also showed 
that EPO attenuated SAH-induced 
brain  injury. Further evidence for the 
bene ficial effect in the setting of SAH 
has also been provided by an experimen-
tal SAH model where a single dose of 
EPO (400 IU/kg) given subcutaneously 
prevented SAH-induced impairment of 
CBF autoregulation (89). Further evidence 
confirmed this observation (90). An addi-
tional experiment has confirmed the neu-
roprotective properties exerted by EPO by 
measuring the S-100 protein concentration 
in CSF of SAH-injured rabbits (38). The 
findings of this study indicated that high 
levels of S-100 protein correlated with 
mortality rate, neurological outcome, and 
ischemic brain damage. Animals treated 
with rHuEPO were found to have signi-
ficantly lower levels of S-100 protein in 
their CSF, no deaths, favorable neurolog-
ical outcome and significant protection 
against brain ischemic damage.
In a recent experimental study, recom-
binant adenoviral vectors (109 plaque- 
forming units per animal) encoding genes 
for human EPO (AdEPO), and β-galacto-
sidase were injected immediately after 
injection of autologous arterial blood into 
the cisterna magna of rabbits, resulting in 
significant reversal of arterial vasospasm 
(70). Subsequent experimental studies 
have tried to provide new insight into the 
mechanisms underlying EPO-mediated 
neuroprotection. In particular, Cheng and 
collaborators (91) investigated whether 
rhEPO administration influenced the endo-
thelial cell apoptosis in the basilar artery 
after SAH in the rabbit. They also inves-
tigated the modulation of rhEPO on the 
activity of JAK2 and STAT3 as part of the 
signaling in apoptotic mechanisms. As a 
result, they found that administration of 
rhEPO could activate JAK2 and STAT3 in 
the basilar artery and decrease the apop-
tosis index of endothelial cells following 
SAH. Moreover, the antiapoptotic genes,  
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CONCLUsION
To date, all phase III trials using neu-
roprotective drugs have failed in demon-
strating efficacy, thus suggesting that 
great optimism can lead to premature 
clinical trials driven by wishful thinking 
instead of detailed scientific evidence.
Further studies must be tailored and 
performed to assess the safety of EPO 
in the setting of this delicate clinical 
application. Optimal tolerated dosages, 
therapeutic time window and duration 
of therapy must be clearly identified. 
Furthermore, since increased blood vis-
cosity and thro mbotic events appear to 
be the major com plications for chronic 
EPO administration, new EPO-derived 
drugs without erythropoietic effects 
(32,97) developed and experimentally 
tested with efficacy at present, should be 
further investigated to tailor successful 
future clinical trials.
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